

GRANT NUMBER DAMD17-94-J-4284

TITLE: Role of CD44 in Tumor Progression

PRINCIPAL INVESTIGATOR: Charles Underhill, Ph.D.

CONTRACTING ORGANIZATION: Georgetown University
Washington, DC 20057

REPORT DATE: September 1998

TYPE OF REPORT: Annual

PREPARED FOR: Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE September 1998	3. REPORT TYPE AND DATES COVERED Annual (1 Sep 97 - 31 Aug 98)	
4. TITLE AND SUBTITLE Role of CD44 in Tumor Progression			5. FUNDING NUMBERS DAMD17-94-J-4284	
6. AUTHOR(S) Charles Underhill, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Georgetown University Washington, DC 20057			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Commander U.S. Army Medical Research and Materiel Command Fort Detrick, Frederick, MD 21702-5012			10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES			19990820 012	
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200) During the previous funding period, we have continued to examine the possibility of targeting lung metastases with proteins derived from cartilage. The rationale behind this approach is that when tumor cells metastasize to the lungs, there is a dramatic increase in the amount of hyaluronan in their immediate vicinity of the tumors. Initially, we had hoped to target this tumor-associated hyaluronan with a binding probe derived from cartilage attached to a chemotherapeutic agent. In this fashion we hoped the tumor cells would take up the complex, degrade it to release the agent and thereby kill themselves. In the course of testing the feasibility of this approach, we have found that the hyaluronan-binding complex by itself (i.e. without being coupled to a chemotherapeutic agent) had a significant effect on the formation of tumor metastases to the lungs. In these experiments, mice were initially injected i.v. with B16 melanoma cells (or Lewis lung tumor cells) and then further injected i.p. with a hyaluronan-binding complex from cartilage. After 2 weeks, the mice were sacrificed and the lungs were evaluated for the presence of tumor nodules. The mice receiving the injections of the complex were found to have fewer and smaller lung metastases than control animals. This result was totally unexpected and may potentially be very important. Our present goal is to determine the mechanism that underlies this phenomenon.				
14. SUBJECT TERMS Human, Anatomical Samples, CD44, Hyaluronan Receptor, Hyaluronan, Extracellular Matrix, Vascularization, Degradation of Extracellular Matrix, Breast Cancer			15. NUMBER OF PAGES 23	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

CBU In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

CBU For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

CBU In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

CBU In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

CBU In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Charles Underhill 9/26/98
PI - Signature Date

TABLE OF CONTENTS:

Front Cover1

SF298 Report Documentation Page.....2

Foreword3

Table of Contents.....4

Introduction5

 Nature of Problem.....5

 Background of Previous Work5

 Purpose of Present Work.....9

 Methods of Approach.....10

Body.....11

Conclusions.....19

References20

Acronyms and Symbols Defined23

Appendix -

INTRODUCTION:

Nature of the Problem:

The present research project is concerned with the interaction between tumor cells and HA (HA), one of the major components of the extracellular matrix. HA is a very large, negatively-charged carbohydrate that functions to maintain the extracellular space. In previous studies, we have shown that the degradation of HA is mediated by a cell surface glycoprotein termed CD44 (also known as the HA receptor). This protein functions to bind HA to the cell surface so that it can be internalized and then degraded by lysosomal enzymes. We have found that this degradatory process can be prevented by antibodies which block the interaction between CD44 and HA.

The working hypothesis of the present application is that this CD44-mediated degradation of HA enhances tumor progression by increasing their vascular supply. This hypothesis is supported by the following lines of evidence. First, a number of studies have shown that the expression of CD44 is causally associated with the metastatic process. For example, transfection of cells with CD44 expression vectors stimulates their metastatic properties. Secondly, human breast cancer cell lines that express CD44 can degrade HA. Thirdly, the fragments of HA produced in the process of degradation have angiogenic properties leading to increased vascularization. And fourthly, large amounts of HA surround many types of blood vessels, and the degradation of this HA by tumor cells would increase their vascular supply.

Background of Previous Work:

General Characteristics of CD44: CD44 defines a family of cell surface glycoproteins which has been implicated in cellular processes such as adhesion, migration, lymphocyte homing and tumor metastasis (1, 2). These proteins are found on a variety of cell types including epithelia, leukocytes, and tumor cells. As a result of alternative splicing and variations in the degree of glycosylation, members of the CD44 family come in several different molecular weight forms, ranging from 80 to well over 200 kDa (2).

As illustrated in *Fig. 1*, CD44 may be divided into three domains, base upon both structural and functional considerations. First, the C-terminal domain of the molecule consists of the transmembrane and cytoplasmic region of the molecule. This region of the molecule can be associated with actin filaments, possibly through an ankyrin-like molecule, and this interaction may be modified by either phosphorylation or acrylation (6-8). The association with the cytoskeleton may be an important factor in determining the distribution of CD44 on the cell surface which, in turn, may influence its ability to interact with HA. Secondly, the middle domain of the molecule is highly glycosylated and in some cases may serve as an attachment site for either chondroitin or heparan sulfate side chains, which are responsible for the




Fig. 1. Model of CD44 and its interactions with the cytoskeleton and HA.

interactions with collagen and fibronectin (9-11). This region of the molecule shows considerable variation in sequence due to alternative splicing of the mRNA. Already, at least 15 isoforms of CD44 have been identified, and most of the different inserts occur in this middle domain (12). And thirdly, the N-terminal domain shares sequence homology with link protein of cartilage and is responsible for the binding of HA. This region recognizes a six sugar sequence of HA, but will also bind chondroitin sulfate with a lower affinity (1, 2).

Involvement of CD44 in Tumor Progression: Recently, several lines of evidence have suggested that CD44 is involved in tumor metastasis. For example, a number of studies have found that high levels of CD44 are associated with certain types of carcinomas, high grade gliomas and many non-Hodgkin's lymphomas (17-19). In the case of lymphomas and other tumors, large amounts of this protein are correlated with the rapid dissemination and negative prognosis of these tumors (18, 19). In preliminary studies, we have also found that the expression of CD44 by a panel of human breast cancer cell lines is correlated with their metastatic behavior as measured by a variety of *in vitro* assays.

More direct evidence that the expression of CD44 is related to the metastatic behavior of tumor cells comes from the work of Gunthert and his associates (20). They found that highly metastatic rat pancreas cell lines express a particular isoform of CD44 (termed CD44v), which was absent from their non-tumorigenic counterparts. More importantly, when non-metastatic cells were transfected with cDNA for this CD44 isoform, they were converted into a more metastatic phenotype (20). In addition, antibodies directed against this particular isoform of CD44 blocked tumor metastasis in experimental models (20). These observations suggest that CD44v is responsible for the metastatic behavior of these cells.

Other isoforms of CD44 also appear to influence the metastatic behavior of cells. Sy et al. (21) have shown that when human lymphoma cells were transfected with the cDNA for a 85 kDa isoform of CD44 which binds HA, there was a marked increase in tumor formation and metastatic behavior, while transfection with an isoform that cannot bind HA had no such effect. In addition, the growth of these tumors *in vivo* could be blocked by co-injection of a soluble form of CD44, which presumably acted by competitively inhibiting the interactions of CD44 with its ligand, HA (22). These researchers also noted that lymphoma cells lacking CD44 also formed both primary and metastatic tumors, albeit at a lower rate. Based on these results, these researchers concluded that expression of the 85 kDa form of CD44 promotes, but is not required for, tumor growth and metastasis (21).

However, none of the studies described above address the mechanism by which CD44 promotes tumor progression. This question is one of the major goal of the present research project.

Role of CD44 in Degradation of HA: One possible mechanism by which CD44 could influence the behavior of tumor cells is by mediating the degradation of HA. Indeed, in earlier studies, we have shown that CD44 is critically involved in the uptake and degradation of HA by both transformed fibroblasts (SV-3T3 cells) and alveolar macrophages (23). To demonstrate this phenomenon, we cultured these cells in the presence of [³H] HA. After various lengths of time, the cultures were digested with pronase to release the HA, and the fragments of [³H] HA were separated from the macromolecular HA by centrifugation through size specific membranes (Cetricon 30 Micro concentrators). Both the SV-3T3 cells and the macrophages degraded significant amounts of the HA. Examination of the digests by molecular-sieve chromatography revealed that the resulting fragments ranged in size from monosaccharides to higher oligosaccharides; smaller fragments were not detected.

CD44 was clearly involved in the degradation of HA, since this process was almost completely blocked by the K-3 mAb against CD44. Furthermore, the degradation was also blocked by the addition of an excess of non-labeled HA, while the addition of other glycosaminoglycans such as dermatan sulfate, chondroitin-4-sulfate and heparin had only a small inhibitory effect (23). This was in keeping with previous studies indicating that CD44 binds with relative specificity to HA as compared to other glycosaminoglycans (1). Similarly, oligosaccharide fragments of HA smaller than a hexasaccharide had only a modest inhibitory effect on the degradation, which is consistent with the size specificity for recognition by CD44 (1).

Collectively, the above results indicated that CD44 plays a key role in the degradation of HA. More specifically, CD44 is responsible for the initial binding of HA to the cell surface so that it can be internalized and degraded by acid hydrolases (see model in Fig. 2). This CD44-mediated uptake is consistent with previous studies suggesting that CD44 is associated with the cytoskeleton (6). Thus, the degradation of HA takes place in a fashion similar to that of other receptor-mediated degradatory processes such as LDL and transferrin.

The ability of cells expressing CD44 to degrade HA may be important during normal processes of tissue morphogenesis and cell migration. For example, during the development of the lungs, there is a progressive decrease in the amount of HA in relation to protein content (24). The decrease reflects the loss of interstitial tissue so that gas exchange can take place at the time of birth. We found that this loss of HA was inversely correlated with the number of macrophages expressing CD44, which increased in number during embryonic development. In addition, histochemical staining revealed that some of these macrophages contained HA in their cytoplasm, suggesting that macrophages had internalized HA from the extracellular matrix. This possibility was further supported by the fact that when new-born mice were injected with the KM-201 monoclonal antibody, which blocks the interaction between HA and mouse CD44, the number of HA-containing macrophages in the lungs decreased while the concentration of HA increased. Taken together, these results suggest that macrophages can internalize HA during lung development and could possibly play a significant role in its removal (24).

CD44 and HA of Human Breast Cancer Cell Lines: In preliminary studies, we have examined the relationship between CD44 expression and the binding and degradation of HA in a panel of human breast cancer cell lines (26). These cell lines have been previously characterized for various markers of invasive potential and represent a convenient *in vitro* model system for studies of breast cancer progression (27).

In general, the cell lines that expressed the most CD44 were also the most invasive, as judged by *in vitro* assays. For example, the Hs578T cell line that expressed the greatest amount of CD44 was invasive, as




Fig. 2. Model of HA degradation. (1) Initially molecules of CD44 are clustered on the cell surface through their interaction with the cytoskeleton. (2) A number of molecules of CD44 bind simultaneously to a molecule of HA. (3 and 4) The HA is endocytosed into a vesicle. (5) Lysosomes fuse with the vesicle. (6) The HA is degraded by the action of acid hydrolases.

judged by migration and chemotaxis in Boyden chamber assays, while the ZR-75-1 cell line, that did not express detectable levels of CD44, was judged to be non-invasive in both of these assays. Similarly, the expression of high amounts of CD44 was generally associated with the lack of estrogen receptors and the presence of the intermediate filament protein vimentin, both of which have been shown to indicate a poor prognosis in human breast cancer (27). This trend is consistent with other studies indicating that the expression of CD44 is correlated with metastatic behavior of tumor cells (17-19)

We then examined the ability of these cells to degrade HA. For this, the cells were cultured in the presence of [³H]HA, and after 40 hours, the resulting fragments were detected using Centricon 30 micro concentrators. The degradation of HA was closely correlated with the amount of CD44 (correlation coefficient, $r = 0.951$). In general, the cell lines that expressed the most CD44 also could degrade the most HA. This correlation was remarkably good, considering the fact that other factors are clearly involved in the degradation process, such as the rate of endocytosis and the amount of lysosomal HAase. The involvement of CD44 in HA degradation was further supported by the observation that Hermes-1 mAb, which is directed against an epitope close to the HA binding domain of CD44 (3), blocked the degradation of HA.

We then examined the distribution of HA in xenografts formed by these cell lines in nude mice. For this, the cell lines were injected into the fat pads of nude mice, and the resulting xenografts were histochemically stained for HA, using a specific probe derived from cartilage. One feature common to all of the grafts was that HA was a prominent component of the matrix at the junction between the graft and the surrounding normal tissue. In some cases, the demarcation boundary between graft and the surrounding tissue was diffuse, while in others it was relatively sharp. The type of boundary differed both from tumor to tumor and within a single tumor.

Significant differences were observed in the distribution of HA within the body of the tumor xenografts. In the grafts of cells that expressed low levels of CD44, HA was generally a major component of the interstitial matrix. In contrast, in the body of grafts formed by cells that expressed high levels of CD44, HA was greatly reduced or absent. These grafts were relatively deficient in interstitial connective tissue and had a more homogenous appearance. The one exception to this correlation was the MDA-468 cell line, in which the amount of HA varied significantly from region to region. However, in general, the expression of CD44 was inversely correlated with presence of HA within the body of the tumor cell xenografts. We speculate that this difference is due to the ability of CD44 expressing tumors to degrade the HA.

Effect of HA Degradation on Vascularization: The central question being addressed in this research project is how does CD44 enhance the metastatic activity of tumor cells. Based upon a variety of evidence, we speculate that the CD44-mediated degradation of HA lead to an increase in the blood supply to the tumor cells which enhances their growth rate as well as their ability to survive and form metastases. This postulated increase in blood supply may occur through two different mechanisms, which may occur simultaneously.

First, the oligosaccharide fragments of HA produced as a by-product of HA degradation may stimulate the formation of new blood vessels. Indeed, studies have shown that oligosaccharide fragments of HA have angiogenic properties. For example, West and coworkers found that fragments of HA 3 to 16 disaccharides in length stimulate the formation of blood vessels when applied to the chick chorioallantoic membrane (28). In contrast, macromolecular HA and fragments of other glycosaminoglycans (chondroitin-

4 and 6-sulfate) were ineffective, suggesting that the effect is specific for HA. These workers went on to show that these oligosaccharide fragments of HA also stimulated the proliferation of endothelial cells in tissue culture (29). This effect appeared to be restricted to endothelial cells since fibroblasts and smooth muscle cells were not effected by these fragments. Presumably, the endothelial cells contain a receptor that can detect fragments of HA. This receptor is probably distinct from CD44 which in most cases is not present on endothelial cells. Along these lines, Banerjee and Toole (30) have shown that antibodies against an HA binding protein on the surface of endothelial cells blocks the migration of these cells. Thus, it is possible that tumor cells expressing CD44 could release fragments of HA which interacts with receptors on the surfaces of endothelial cells and stimulate the formation of new blood vessels.

A second possible mechanism is that tumor cells expressing CD44 can degrade the HA surrounding blood vessels. In histochemical studies, we have examined the distribution of HA surrounding blood vessels in different tissues. In some tissues, such as the liver and spleen, only small amounts of HA are associated with the blood vessels. In contrast, in other tissues such as the dermis, the lamina propria of the intestinal track, the stroma of the lungs and the pericardium of the heart, large amounts of HA are associated with the blood vessels. In these tissues, HA was generally associated with the intima of veins and venules, immediately beneath the endothelial cell lining. In contrast, in arteries, it was generally reduced or absent from the intima, but was present in the adventitia. Thus, the ability of tumor cells to degrade this HA could allow them to get in closer proximity to the blood supply and consequently receive more nutrients. Along these lines, it is also possible that these tumor cells could more easily penetrate the blood vessels, enter the circulation and metastasize to different locations.

We further hypothesize that regardless of the mechanism, the increase in the blood supply results in a selective advantage for those cells that express CD44. When we stain normal mouse mammary tissue for CD44, we find that only small amounts of it are expressed on the ductal cells. However, in primary tumors of transgenic mice, we find that the expression of CD44 is variable. It is present in some regions but absent from others. We speculate that the CD44 expressing cells of the primary tumor are at a selective advantage for giving rise to metastases. One of the specific aims of this research project is to determine if the metastases that arise from these mixed primary tumors have a high probability of expressing CD44.

Purpose of the Present Work:

There are two major aspects of this present progress report. The first part is concerned with our original proposal that the expression of CD44 allows tumor cells to degrade HA, which, in turn, results in an increase in the blood supply (Tasks 1 through 4). However, for technical reasons, we have not made much progress in these tasks.

During the past year, we have made progress on the second part which is concerned with the HA that is associated with lung metastases. We found that tumors that have metastasized to the lungs are associated with large amounts of HA in the surrounding tissue. This HA may have been produced by the normal lung tissue as part of an immune response. This phenomenon suggested the possibility of targeting these tumors with complex of HA binding proteins isolated from cartilage termed PG. The feasibility of this approach was examined in Tasks 5 through 7. In the course of carrying out these studies, we found that the PG complex by itself appears to have anti-metastatic properties. In particular, when it is injected i.p. into experimental mice that had been previously injected i.v. with tumor cells, then the number and size of lung metastases is greatly reduced (Task 8). We now propose to determine the molecular basis for this phenomenon.

Methods of Approach:

1. *Examine the effect of CD44 expression of the vascularization of tumors:* To determine if the expression of CD44 leads to an increase in the vascular supply, we will transfect a human breast cancer cell line with a CD44 expression vector, and inject these cells into nude mice and allow them to grow. The resulting xenografts will be and examined for the presence of blood vessels. If our hypothesis is correct, then xenografts derived from CD44 positive cells should be associated with a greater number of blood vessels than the CD44 negative cells.
2. *Determine the effects of various agents on the vascularization of tumors expressing CD44:* Osmotic pumps that release either control or blocking antibodies to CD44 will be implanted subcutaneously in nude mice along with tumor cell lines that express CD44. After a period of growth, the xenografts will be removed and examined histologically for blood vessels. If our working hypothesis is correct, then the blocking antibodies should inhibit the vascularization of the tumor cells.
3. *Examine the expression of CD44 in primary and secondary tumors of transgenic mice:* According to our working hypothesis, the expression of CD44 imparts a selective advantage to cells with regard to tumor progression. To test this possibility, we will examine both primary and secondary tumors formed by transgenic strains of mice that spontaneously develop breast tumors. The xenografts will be analyzed histochemically for endothelial cells.
4. *Survey specimens of human breast tumor for the presence of CD44, HA and vascular endothelial cells:* To determine the significance of CD44, HA and endothelial cells in evaluating its metastatic potential, we will examine specimens of human breast cancer. If this pilot experiment shows a good correlation between these parameters, then we will expand this study to include a greater number of samples.
5. *To examine various types of lung metastases for the expression of HA:* In previous experiments, we observed that HA was often associated with lung metastases. To determine if this phenomenon is universal, we will examine a number of other systems involving metastases to the lungs.
6. *To test the possibility of using PG to target lung metastases:* To determine if the tumor-associated HA can be targeted with PG, we will inject a biotinylated form of this complex (b-PG) into mice that had tumor metastases. We then examined the lungs of this mouse to determine if the b-PG had gained access to the HA associated with the lung metastases.
7. *To examine the effects of PG coupled to MTX on cultured tumor cells:* To test the feasibility of using derivatives of PG to deliver chemotherapeutic drugs to tumor cells, we will couple methotrexate (MTX) to PG and test its ability to kill tumor cells in culture.
8. *To determine the effect of HA-binding proteins on experimental lung metastasis:* The effect of PG on experimental models of lung metastasis will be examined. For this, syngenic mice will be given i.v. injections of tumor cells (Lewis lung and B16). Three days after this initial injection, the mice will be given i.p. injections of the PG and after 2 weeks, the mice will be sacrificed and the lungs will be evaluated for the number of metastases.

BODY

Introduction: During the previous funding period, we have concentrated our efforts on targeting tumor cells with a HA-binding probe derived from cartilage (the PG complex). As described in previous reports, we had found that when some types of breast cancer cells metastasize to the lungs, the surrounding lung tissue produces large amounts of HA. This phenomenon presented the possibility of using this HA to target the tumors in the lungs with an HA-binding complex derived from cartilage that is composed of proteoglycan and link protein (PG). To test the feasibility of this approach, we had coupled the chemotherapeutic agent methotrexate (MTX) to PG and found that it displayed cytotoxic activity on cultured tumor cells. More recently, as a control for these studies, we tested the PG preparation directly in animal models of metastasis. Much to our surprise and delight, we found that the PG complex by itself (even without the chemotherapeutic agent) significantly down-regulated the frequency of lung metastasis. These intriguing results will be described in greater detail in the new Task 8.

In the following sections, we will discuss both the old and the new Tasks. Since the old tasks have been described in previous progress reports, we will present only brief summaries of these. In the case of the new Task 8, these recent results will be described in greater detail. As indicated above, we are very excited about the potential significance and implications of the phenomenon described in Task 8.

Task 1: Examine the effect of CD44 expression of the vascularization of tumors: The purpose of this study was to test the hypothesis that CD44 enhances the vascularization of tumors. To accomplish this, we proposed to transfect human breast cancer cell lines with a CD44 expression vector, grow these cells in nude mice, and then analyze the resulting xenografts for endothelial cells.

Previous results: As described in the previous progress report, we transfected a number of human breast cancer cell lines (ZR-751, MCF-7, and ML-20) with an expression vector for human CD44. We characterized several clones of the transfected cells and found that they gained the ability to bind and degrade HA in a CD44-dependent fashion as we had predicted. However, when these cells were injected into the fat pads of nude mice, none of them grew despite repeated attempts under a variety of conditions (i.e. with and without Metragel and estrogen). Thus, we have been unable to test the hypothesis that the expression of CD44 allows the tumor cells to degrade the HA in the extracellular matrix and stimulate angiogenesis. We conclude from this that transfection with CD44 does not confer increased growth potential in nude mice, at least in the case of the human breast cancer cell lines. This is in keeping with the results from other laboratories that increased metastatic potential following transfection with CD44 expression vectors is very dependent upon the cell type being transfected. Thus, at this point, we have attempted this experiment with all of the appropriate human breast cancer cell lines at our disposal. While we have not given up on this approach, we are somewhat frustrated.

Recommendations: The only possibility left to us is to attempt this experiment with other cell lines. According, we propose to examine cell lines that are derived from different types of tumors (lung, prostate, colon etc.) and of a mouse origin instead of human. These cell lines must satisfy the following criteria: 1) they must not grow too aggressively in nude mice; and 2) they should express low levels of endogenous CD44.

Task 2. Determine the effects of various agents on the vascularization of tumors expressing CD44: The purpose of this set of experiments was to determine if vascularization of xenografts could be blocked by antibodies to CD44 or enhanced by fragments of HA or HAase. As described above, we have been

unable to get the transfected cell lines to grow in the nude mice. Thus, no further progress (other than the preparation of reagents) has been made on this task.

Recommendations: Again, we must wait for progress in Task 1.

Task 3. Examine the expression of CD44 in primary and secondary tumors of transgenic mice: The purpose of this set of experiments was to compare primary versus secondary tumors with respect to the expression of CD44 and HA. For this, we examined a strain of mice that has been transfected with a polyomavirus middle T oncogene under the control of a mouse mammary tumor virus promoter/enhancer (31). This transgenic strain of mice forms multifocal mammary adenocarcinomas that metastasize to the lungs at a high frequency. The results of this study form the foundation of the new Tasks 5, 6 and 7.

Previous results: A mouse with a large tumor load was sacrificed and both the primary tumor and the lungs were removed and fixed overnight in formaldehyde. The tissues were then embedded in polyester wax, which helps to preserve the antigenicity (32) and then stained for both CD44 using the KM-201 mAb and HA using the b-PG probe.

Results and Discussion: As described in the previous progress report, the primary tumor present in the breast tissue was heterogeneous with respect to the expression of both CD44 and HA. The amount of CD44 appeared to be highest at the edge of the primary tumor and decrease towards the center of the mass. A similar type of pattern was observed with the HA, with the highest concentration again towards the edge of the tumor.

We then examined the distribution of CD44 in secondary tumors that were present in the lung tissue, and found that its distribution was similar to that of the original tumor, with positive staining on the cells located on the periphery and much less staining in the center of the tumor mass. In addition, a large number of macrophages that also stain for CD44 were apparent in the vicinity of the tumor, while adjacent sections of normal lung tissue contained far fewer macrophages. This was consistent with other studies showing that many tumors are associated with macrophages (34, 35). Interestingly, it appeared that many of these macrophages are aggregated, perhaps as a response to elevated levels of HA.

When the lung tissue was stained for HA, large amounts of HA were present in the alveolar tissue surrounding the tumor mass. In contrast, adjacent normal lung tissue contained low levels of HA, most of which was present in the connective tissue surrounding the major blood vessels and air passage ways. It appeared that while some of the HA was associated directly with the tumor itself, much of the HA was located some distance away from the tumor mass in the surrounding normal tissue, suggesting that it was derived from the normal lung tissue perhaps as a result of a localized immune response. Along these lines, other studies have shown that an inflammatory response in the lungs results in increased levels of HA (36-38). It is also possible that this HA accounts for the observation described above that many of the macrophages in the vicinity of the tumor were clumped together, since we had previously shown that HA can induce these cells to aggregate by interacting with CD44 present on these cells (39).

This high levels of HA associated with the metastatic tumors in the lungs may have important implications. In particular, it suggested the possibility that this HA could be used to locate and target tumor metastases. This could be accomplished with the HA binding complex from cartilage that we had used previously as a histochemical stain for HA. This PG probe consists of a trypsin fragment of the aggrecan molecule along with an associated link protein that bind to hyaluronan with both high affinity and specificity (40). It may be possible to attach chemotherapeutic agents to this PG and inject this into individuals with tumors.

Recommendations: The observation concerning the association of HA with tumor metastasis should be investigated further (see Tasks 5, 6, 7 and 8).

Task 4. Survey specimens of human breast tumor for the presence of CD44, HA and vascular endothelial cells: The purpose of this study was to determine if the expression of CD44 and HA was correlated with the distribution of blood vessels and if this could be used as a diagnostic indicator of tumor behavior. For this, we have made use of the Breast Cancer tumor bank which is one of the core facilities of the Lombardi Cancer Center. Samples were selected from the tumor bank based upon the availability of specimens representing a spectrum of invasive tissue types including normal, ductal carcinoma *in situ*, and metastasis in the lymph nodes.

Previous results: As described in the previous progress report, when we examined normal breast tissue, we found that small amounts of CD44 were associated with the ductal cells and that HA was present in the stroma immediately surrounding the glandular epithelium, but was reduced or absent in regions located a short distance from the epithelium. In regions of invasive carcinoma and ductal carcinoma *in situ*, the tumor cells expressed high levels of CD44 and high levels of HA were associated with the surrounding stroma but was generally absent from the tumor mass. Finally, in the case of secondary tumors present in the lymph nodes, the expression of both CD44 and HA was variable. Taken together, these results indicate that while CD44 was not consistently associated with metastatic tumors, it was associated with the presence or absence of HA in the tumor mass.

More recently, we have extended this study to examine the distribution of both HA blood vessels (endothelial cells). Paraffin sections of human breast cancer from the core facilities of the Lombardi Cancer Center were simultaneously stained for both HA and endothelial cells. The association between HA and endothelial cells was also found to be quite variable. In one tumor sample, blood vessels were present in the stroma surrounding the tumors that contain very little HA. However, in another tumor sample, there were large numbers of capillaries in matrix that is rich in HA. Thus, there is not a consistent correlation between the expression of HA and the presence or absence of blood vessels. However, this does not necessarily disprove the hypothesis that fragments of HA can induce angiogenesis, since the HA may have been there originally when the blood vessels were initially formed and then subsequently lost. Thus, it is unclear if the distribution of HA has any predictive value in determining tumor angiogenesis.

Recommendations: While we have not found any consistent pattern between the distribution of HA and endothelial cells. We recommend no further action on this Task at present.

Task 5: To examine various types of lung metastases for the expression of HA: As described above, the purpose of this set of experiments was to determine if metastases to the lungs are associated with increased levels of HA in the surrounding tissue. While this was clearly the case for the transgenic mouse described in Task 3, the question remained as to whether or not this is a generalized phenomenon for all forms of lung metastases. To answer this question, we examined the nude mice that had been given injections of human breast cancer cell lines as well as lung biopsies containing metastases from human patients suffering from breast cancer

Xenografts of human breast cancer cells in nude mice: In these experiments, MDA-231 and Hs578T cells (human breast cancer cell lines) were injected into the tail vein of nude mice and after one week, the mice were sacrificed and the lung tissue was collected. The lung tissue was embedded in paraffin, processed for

histology and then stained for HA using the b-PG probe. The results showed that large amounts of HA staining were associated with the tumor nodules in the lungs. In these cases, the HA appeared to be present in the normal tissue surround the tumor. Similar results were obtained when we examined biopsies of lung tissues from human patients suffering from breast cancer (from the core facilities of the Lombardi Cancer Center). In most, but not all cases, elevated levels of HA were present in the normal stroma surrounding the tumors. We believe that the more advanced the tumor is, the less likely that it will be associated with HA.

Results and Discussion: Similar results were obtained when we examined several different models of tumor metastasis. In most, but not all cases, we observed that large amounts of HA surrounded tumor nodules present in the lungs. In general, greater amounts of HA tended to be associated with newly formed tumors and much less with those that had been present longer. These results suggest that when tumor cells initially metastasize to the lungs, they initiate a response that induces the synthesis of HA.

At present the nature of the signal leading to the increase in HA production is not clear. One possibility is that the tumor cells initiate an immune response in the lung tissue that causes the normal lung cells to produce HA. This is consistent with previous studies that have found that inflammation in the lungs results in an increase in the production of HA (36-38). Along these lines, in preliminary studies we have found that dexamethasone treatment tends to down-regulate the HA associated with lung metastases, suggesting that it is part of an immune response. Interestingly, dexamethasone also stimulated the growth of tumors in the treated animals (data not shown).

Recommendations: If the tumor-associated HA is to be clinically useful, then it should also occur with other types of primary tumors (e.g. prostate and colon cancers) and on metastases present in other organs (e.g. the liver and lymph nodes). For this reason, we propose to extend this study to include other types of tumors and different sites of metastasis.

Task 6: To test the possibility of using PG to target lung metastases: The fact that HA is often associated with lung metastases suggested the possibility that it might be used to target these tumors using the HA-binding proteins from cartilage. To test this possibility, we injected a biotinylated form of the cartilage proteoglycan (b-PG) into mice that had tumor metastases. We then examined the lungs of this mouse to determine if the b-PG had gained access to the HA associated with lung metastases.

Previous studies: In these studies, we used the α -18 cell line, which is derived from MCF-7 cells that has been transfected with a bacterial *Lac-Z* gene. This allows the tumor to be easily located by staining with X-gal that gives a blue color. These cells have also been transfected with an expression vector for FGF-1 which allows them to metastasize to the lungs (41). These cells were injected into the mammary fat pads of 6-8 week-old nude mice and allowed to grow to form primary tumors of 1-2 gm and at the same time form spontaneous metastases to the lungs. These mice were then given i.v. injections of 200 μ g of the b-PG. Twenty four hours after the injection, the mice were sacrificed, and the lung tissue was fixed in 3.7% formalin, stained with X-gal and processed for histology.

Results and Discussion: The histochemical staining showed that in many cases, the metastasis of the α -18 cell were closely associated with the b-PG. Thus, it would appear that under the conditions used, the b-PG can exit the blood vessels and interact with the HA associated with the tumor cells. Thus, it may indeed be possible to use the PG complex to target lung metastases. The probe does appear to be preferentially associated with the α -18 cells present in the lungs. Thus, it may be possible to couple chemotherapeutic

agents to the PG complex. It is our hope that in the vicinity of the metastasis, this complex this would be taken up by the tumor cells or by the associated macrophages. When the cells degrade the complex in the lysosomes, the chemotherapeutic agent would be released and kill the growing tumor cells. If the chemotherapeutic agent were cell-cycle dependent, then the tumor cells may be more susceptible than the associated macrophages which are post mitotic.

Recommendations: The results of these studies suggest that it is possible to target the HA associated with lung metastasis. This will be further evaluated in Tasks 7 and 8.

Task 7: To examine the effects of PG coupled to MTX on cultured tumor cells: As described above, we believe that drugs attached to the PG will bind to the tumor-associated HA and will be taken up by the tumor cells (or macrophages) using a CD44 dependent mechanism. In preliminary studies, we have examined the ability of PG coupled to a chemotherapeutic drug to kill tumor cells in culture. For this experiment, we used methotrexate (MTX), which is widely used as a chemotherapy drug (42, 43).

Previous results: We prepared a conjugate of MTX and PG according to the methods described by Kulkarni (44). When this conjugate was added to cultures of rat fibrosarcoma (RFS) cells, it significantly inhibited their proliferation. Indeed, the activity of the MTX-PG was approximately the same as that of equivalent amount of MTX by itself. In general, when a drug has been coupled to a proteins such as an antibody, it loses its toxicity (45, 46). This is not surprising since the complex must be internalized and degraded by the tumor cell before the coupled drug will be released and exert its activity. Thus, the fact that the complex of MTX-PG is active is a very encouraging.

Recommendations: When we initially started these experiments, we thought that the chemotherapeutic drug was necessary for its potential anti-tumor activity. As will be described in the following section, we now know that the PG by itself has anti-metastatic activity. For this reason, we propose to concentrate our efforts on further characterizing the effects of the PG.

Task 8. The effect of HA-binding proteins from cartilage on experimental lung metastasis: In the course of studying the feasibility of using the PG from cartilage to target lung metastases, we decided to test the effect of the PG by itself on the formation of experimental metastasis. Initially, these experiments were carried out simply as a control to establish a base line for the PG before derivation with the chemotherapeutic agent. Much to our surprise, we found that the PG by itself had a substantial effect on the formation of experimental metastases. We are very excited about these results since they promise a new avenue for the prevention of metastasis. These preliminary results which were carried out in conjunction with Dr. Shawn Green of EntreMed (Rockville, MD), are described in the following sections.

Isolation of the HA-binding complex: The isolation of the PG complex from cartilage was based upon a procedure described by Dr. Tengblad (47) and consisted of three major steps (40). In the first step, bovine nasal cartilage was shredded with a sureform blade and then extracted overnight with 4 M guanidine HCl, 0.5 M Na acetate pH 5.8, followed by dialysis against distilled water and lyophilization. In the second step, 3 gm of the lyophilized extract was dissolved in 100 ml of 0.1 M Hepes, 0.1 M Na acetate pH 7.3 buffer and digested with 1.6 mg of purified trypsin at 37°C. After 2 hours, the digestion was stopped by the addition of 2 mg of soybean trypsin inhibitor. In the third step, the digested extract was mixed with HA coupled to Sepharose (HA-Sepharose), and dialyzed first against 4 M guanidine HCl, 0.5 M Na acetate pH 5.8, and then against 10 volumes of distilled water. The HA-Sepharose was then packed into a

chromatography column, washed with 1.0 M NaCl followed by a gradient of 1.0 to 3.0 M NaCl. The PG complex was eluted from the column with 4 M guanidine HCl, 0.5 M Na acetate pH 5.8, dialyzed against saline and then sterilized by passage through a 0.2 μ m pore filter.

Model systems of Metastasis (Lewis lung tumor and B16 melanoma model systems): In most experiments, freshly passaged tumor cells (2×10^6 Lewis Lung cells, 5×10^4 B16 melanoma cells) were injected via the tail vein into syngenic mice (C57BL/6 for the B16 melanoma). Three days later, the mice were given i.p. injections of varying amounts of the PG complex which were repeated on a daily basis until day 13. On day 14, the mice were sacrificed and the lung tissue was examined for the presence of tumors. In the case of the B16-BL6 melanoma cells, the number of surface metastases was determined by visual examination under a dissecting microscope. In the case of the Lewis lung cells, the lungs were weighed as a reflection of the tumor mass.

Results and Discussion: The PG complex used in this study was isolated from bovine nasal cartilage by a limited trypsin digestion followed by affinity chromatography on hyaluronan coupled to Sepharose. polyacrylamide gel electrophoresis of this complex revealed that it consisted of two proteins, a trypsin fragment of the core protein of aggrecan and one of the link proteins (see arrows in Fig. 3). Together these proteins bind to hyaluronan with high affinity and specificity (40).




Fig. 3. SDS-PAGE analysis of different preparations of PG. All of the preparations were isolated by affinity chromatography on a HA-Sepharose column. The samples were processed for electrophoresis on a 10% SDS-polyacrylamide gel under reducing conditions. The HA-binding fragment of the aggrecan is indicated by the arrow on the right (\cong Mr 75) and the trypsin-resistant link protein is indicated by the arrowhead on the right (\cong Mr 43k).

In initial experiments, we examine the effect of the PG complex on the Lewis lung model of tumor metastasis. For this, three groups of mice were given an i.v. injections of 2×10^6 Lewis lung cells on day 0 and beginning on day 3, the mice were given daily i.p. injections of the PG complex (0, 15 and 49 μ g/injection). Finally, on day 13 the mice were sacrificed and their lungs were removed for examination. Figure 4 shows that the lungs from the control mice (i.e. receiving only saline) had numerous metastases,

while those from mice that had been injected with the PG complex (49 $\mu\text{g}/\text{injection}$) displayed far fewer metastases. This difference in tumor burden was also reflected by the gross weights of these lungs. Figure 5 shows that the weight of the lungs from the control group was significantly heavier than that of both groups of mice receiving the injections of the PG complex. In addition, the higher concentration of PG complex inhibited the growth of the Lewis lung cells to a greater extent than the lower concentration, suggesting that this response shows a dose dependency. Thus, the i.p. injection of the PG complex inhibited the growth of Lewis lung tumor cells in this model system of tumor metastasis.

Effect of Hyaluronan Binding Protein on Experimental Lung Metastasis (Lewis Lung Cells)




Fig. 4. Lungs from control and PG injected mice. The top row shows the lungs from control mice 13 days following the i.v. injection of Lewis lung cells that had received daily injections of saline. Numerous small nodules are apparent on the surface of the lungs. The bottom row shows lungs from mice that had received i.p. injections of the PG complex (49 $\mu\text{g}/\text{injection}$). There is an obvious reduction in the number of tumor nodules on the lungs.




Fig. 5. Weights of lungs from control and PG injected mice. The average and standard deviation of the weights from control (saline injected) and PG injected mice are shown ($n=4$ in each group). The PG treatment significantly reduced the lung weight, which is a measure of tumor burden. This effect appeared to be dose dependent in that the 49 μg of PG per injection was had a greater effect than 15 μg .

To determine if a similar response occurred in other models systems as well, we examined the B16-BL6 melanoma cells. In this model system, syngenic mice were injected i.v. with 5×10^4 B16-BL6 cells, and beginning three day later the mice were given daily injections of the various test agents. After 13 days, the mice were sacrificed and the lungs were removed for examination. As shown in Fig. 6, there was an obvious difference between the lungs of mice injected with saline (control) and those injected with the PG complex. However, microscopic examination showed that small tumor nodules were also present in the lungs of the PG injected mice. This difference was also apparent when the number of tumor nodules was enumerated. Figure 7 shows that the i.p. injection of the PG complex, significantly reduced the number of obvious nodules in a dose dependent fashion, with the E.D.₅₀ being approximately 10 μg per injection. In contrast, the injection of BSA had no discernable effect on the number of metastases. Clearly, the PG complex inhibited the growth of the tumor nodules.

**Effect of Hyaluronan Binding Protein on
Experimental Lung Metastasis (B16 melanoma cells)**



Fig. 6. Photo of lungs from control and PG injected mice. The top row shows the lungs of control mice that had been injected i.p. with saline while the bottom row show the lungs of mice that had been injected with the PG complex.




Fig. 7. Bar graph showing dose response curve of PG on number of lung metastases. Compared to an equivalent amount of BSA, the PG complex reduced the number of metastases larger than 0.5 mm.

This phenomenon appears to depend on the HA binding activity of the PG complex. As shown in Fig. 7, if the PG complex is first mixed with HA and then injected into the peritoneal cavity of the mice, then the inhibitory effect on the number of lung metastases was abolished. In a similar fashion, if the PG complex was first placed in a boiling water bath prior to the i.p. injections, then the inhibitory effect was blocked (data not shown). These results suggest to us that the ability to bind HA is required for the anti-metastatic activity of the PG complex.

At present, we do not know how the PG complex is acting. One possibility is that it inhibits the formation of new blood vessels to the lung tumors. In other words, it acts an inhibitor of angiogenesis. To test this possibility, we have initiated experiments with Dr. Shawn Green to examine the effects of PG on endothelial cells growing in culture. Very preliminary results have suggested that the complex is a potent inhibitor of endothelial cells migration as determined by a wound healing assay. While these results need to be confirmed, such an effect could account for the activity of the PG complex. In addition, this could also account for the fact that co-injection of HA and the PG complex blocked its activity. Presumably, in this case, the complex is bound to the HA in the peritoneal cavity and is prevented from entering the circulation where it could block the vascularization of the tumor cells.

Recommendation: We strongly feel that these results should be pursued with the utmost vigor. Clearly there are a number of questions that need to be addressed. First, is the PG complex is effective against other types of tumors? Secondly, does it block metastasis to other sites in the body in addition to the lungs? And thirdly, what is the mechanism by which PG is able to inhibit metastasis? During the non-funded extension of this grant, we will address these issues.

CONCLUSIONS:

Implication of Completed Research (both old and new):

- 1) Both primary and secondary tumors of breast cancer are heterogeneous with respect to the expression of CD44. Thus, there does not appear to be a close correlation between the expression of CD44 and the formation of metastases.
- 2) In general, there is an inverse correlation between the expression of CD44 and the presence of HA. Presumably, this is due to the fact that CD44 allows cells to take up and degrade HA. However, exceptions to this were noted in several cases. It is possible that in these regions, the extent of HA synthesis is so great, that the CD44 mediated degradation is not sufficient to remove all of it.
- 3) The presence of HA does not appear to be directly correlated with the distribution of endothelial cells (blood vessels) in biopsies of human breast cancer.
- 4) Large amounts of HA are associated with tumors that have metastasize to the lungs. This phenomenon may be useful for targeting agents to the tumors.
- 5) When b-PG is injected into mice, it can become preferentially associated with tumor metastases present in the lungs.
- 6) A complex consisting of MTX coupled to PG is active in blocking the proliferation of tumor cells in culture.
- 7) The PG complex is able to inhibit the formation of lung metastases in animal models.

Recommended Changes:

- 1) Task 8 should be expanded to verify the results and to determine the mechanism by which the PG is inhibiting the formation of metastases.

REFERENCES:

1. Underhill, C. B. 1989. The interaction of hyaluronate with the cell surface: the hyaluronate receptor and the core protein. in *The Biology of Hyaluronan*. Wiley, Chinchester Ciba Foundation Symposium **143**:97-106
2. Underhill, C. B. 1992. CD44: The Hyaluronan Receptor. *J. Cell Sci.* **103**: 293-298
3. Culty, M., Miyake, K., Kincade, P. W., Sikorski, E., Butcher, E. C., and Underhill, C. B. 1990. The hyaluronan receptor is a member of the CD44 (H-CAM) family of cell surface glycoproteins. *J. Cell Biol.* **111**:2765-2774.
4. Miyake, K, Underhill, C. B., Lesley, J., & Kincade, P. W. 1990. Hyaluronate can function as a cell adhesion molecule and CD44 participates in hyaluronate recognition. *J. Exp. Med.* **172**, 69-75.
5. Aruffo, A., Stamenkovic, I., Melnick, M., Underhill, C. B. & Seed, B. 1990. CD44 is the principal cell surface receptor for hyaluronate. *Cell* **61**:1303-1313.
6. Lacy, B. E., & Underhill, C. B. 1987. The hyaluronate receptor is associated with actin filaments. *J. Cell Biol.* **105**:1395-1404.
7. Kalomiris, E. L. and Bourguignon, L. Y. W. 1989. Lymphoma protein kinase C is associated with the transmembrane glycoprotein, GP85, and may function in GP85-ankyrin binding. *J. Biol. Chem.* **264**: 8113-8119.
8. Bourguignon, L. Y. W., Kalomiris, E. L., and Lokeshwar, V. B. 1991. Acylation of the lymphoma transmembrane glycoprotein, GP85, may be required for GP85-ankyrin interaction. *J. Biol. Chem.* **266**: 11761-11765.
9. Carter, W. G., and Wayner, E. A. 1988. Characterization of the class III collagen receptor, a phosphorylated, transmembrane glycoprotein expressed in nucleated human cells. *J. Biol. Chem.*, **263**:4193-4201,
10. Brown, T., Bouchard, T., St. John, T., Wagner, E. & Carter, W. G. 1991. Human keratinocytes express a new CD44 core protein (CD44E) as a heparin-sulfate intrinsic membrane proteoglycan with additional exons. *J. Cell Biol.* **113**:207-221.
11. Jalkanen, S. & Jalkanen, M. 1992. Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin. *J. Cell Biol.* **116**:817-825.
12. Screaton, G. R., Bell, M. V., Jackson, D. G., Gornelis, R. B., Gerth, U., and Bell, J. I. 1992. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. *Proc. Natl. Acad. Sci. USA*, **89**:12160-12164.
13. Berg, E. L., Goldstein, L. A., Jutila, M. A., Nakache, M., Picker, L. P., Streeter, P. R., Wu, N. W., Zhou, D. & Butcher, E. C. 1989. Homing receptors and vascular addressins: Cell adhesion molecules that direct lymphocyte traffic. *Immunol. Rev.* **108**:5-18.
14. Underhill, C. B. & Dorfman, A. 1978. The role of hyaluronic acid in intercellular adhesion of cultured mouse cells. *Exp. Cell Res.* **117**:155-164.
15. Underhill, C. B., Thurn, A. L. & Lacy, B. E. 1985. Characterization and identification of the hyaluronate-binding site from membranes of SV-3T3 cells. *J. Biol. Chem.* **260**: 8128-8133.
16. Stamenkovic, I., Amiot, M., Pesando, J. M., and Seed, B. A. 1989. Lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. *Cell*, **56**:1057-1062
17. Kuppner, M. C., Meir, E. V., Gauthier, T., Hamou, M. -F., and De Tribolet, N. 1992. Differential expression of the CD44 molecule in human brain tumours. *Int. J. Cancer* **50**:572-577.
18. Horst, E., Meijer, C. J. L. M., Radaszkiewicz, T., Ossekoppele, G. J., Van Krieken, J. H. J. M., and Pals, S. T. 1990. Adhesion molecules in the prognosis of diffuse large-cell lymphoma: Expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18), and ICAM-1 (CD54). *Leukemia*, **4**:595-599.

19. Matsumura, Y., and Tarin, D. 1992. Significance of CD44 gene products for cancer diagnosis and disease evaluation. *Lancet* **340**:1053-1058.
20. Gunthert, U., Hofmann, M., Rudy, W., Reber, S., Zoller, M., Hausmann, I., Matzku, S., Wenzel, A., Ponta, H., and Herrlich, P. 1991. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. *Cell*, **65**:13-24.
21. Sy, M. S., Guo, Y., and Stamenkovic, I. 1991. Distinct effects of two CD44 isoforms on tumor growth in vivo. *J. Exp. Med.*, **174**:859-866.
22. Sy, M. S., Guo, Y. J. & Stamenkovic, I. 1992. Inhibition of tumor growth in vivo with a soluble CD44-immunoglobulin fusion protein. *J. Exp. Med.* **176**:623-627.
23. Culty, M., Nguyen, H. A., and Underhill, C. B. 1992. The hyaluronan receptor (CD44) participates in the uptake and degradation of hyaluronan. *J. Cell Biol.*, **116**:1055-1062.
24. Underhill, C. B., Nguyen, H. A., Shizari, M., and Culty, M. 1992. CD44 positive macrophages take up hyaluronan during lung development. *Devel. Biol.* **155**:324-336 lungs
25. Underhill, C. B. 1993. Hyaluronan is inversely correlated with the expression of CD44 in the dermal condensation of the embryonic hair follicle. *J. Invest. Derm.* in press.
26. Culty, M., Shizari, M., Thompson, E.W., and Underhill, C.B. 1994 Binding and degradation of hyaluronan by human breast cancer cell lines expressing different forms of CD44: Correlation with invasive potential. *J. Cell Physiol.* **160**: 275-286.
27. Thompson, W. W., Paik, S., Brunner, N., Sommers, C. L., Zugmaier, G., Shima, T. B., Torri, J., Donahue, S., Lippman, M. C., Martin, G. R., and Dickson R. B. 1992. Association of increased basement membrane-invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. *J. Cell. Phys.*, **150**:534-544.
28. West, D. C., Hampson, I. N., Arnold, F., and Kumar, S. 1985. Angiogenesis induced by degradation products of hyaluronic acid. *Science*, **228**:1324-1326.
29. West, D. C. and Kumar, S. 1989. The effect of hyaluronate and its oligosaccharides on endothelial cell proliferation and monolayer integrity. *Exp. Cell Res.* **183**:179-196.
30. Banerjee, S. D. and Toole, B. P. 1992. Hyaluronan-binding protein in endothelial cell morphogenesis. *J. Cell Biol.* **119**:643-652.
31. Guy, C. T., R. D. Cardiff and W. J. Muller. 1992. Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease. *Molec. Cell. Biol.* **12**:954-961.
32. Kusakabe M, Skakura T, Nishizuka Y, Sano M, Matsukage A: 1984. Polyester wax embedding and sectioning technique for immunohistochemistry. *Stain Technol* **59**:127-132
33. Graham, R. C., Lundholm, U., and Karnovsky, M. J. 1965. Cytochemical demonstration of peroxidase activity with 3-amino-9-ethyl carbazole. *J. Histochem. Cytochem.*, **13**:150-158.
34. Mantovani, A., Ming, W. J., Balotta, C., Abdeljalil, B., and Bottazzi, B. 1986. Origin and regulation of tumor-associated macrophages: the role of tumor-derived chemotactic factor. *Biochem. Biophys. Acta* **865**: 59-67
35. Brunda, M. J., Sulich, V., Wright, R. B. and Palleroni, A. V. 1991. Tumoricidal activity and cytokine secretion by tumor-infiltrating macrophages. *Int. J. Cancer* **48**:704-708.
36. Nettelbladt, O., Beergh, J., Schenholm, M., Tengblad, A., Halgren, R. 1989. Accumulation of hyaluronic acid in the alveolar interstitial tissue in bleomycin-induced alveolitis. *Am. Rev. Respir. Dis.* **139**: 759-762
37. Sahu, S. 1980. Hyaluronic acid - an indicator of the pathological conditions of human lungs. *Inflammation* **4**: 107-112
38. Sahu, S.C. and Ulsamer, A.G. 1980. Hyaluronic acid - an indicator of pulmonary injury? *Toxicol. Lett.* **5**: 283-286.

39. Green, S.J., Tarone, G. and Underhill, C.B. 1988 Aggregation of macrophages and fibroblasts is inhibited by a monoclonal antibody to the hyaluronate receptor. *Exp. Cell Res.* 178: 224-232
40. Green, S.J., G. Tarone, and C. B. Underhill. 1988. Distribution of hyaluronate and hyaluronate receptors in the adult lung. *J. Cell Sci.* 89:145-156.
41. Zhang, L., Ding, I. Y. F., Kharbanda, S., Chen, D. Mcleskey, S. W., Honig, S., Kern, F. G.: 1997. MCF-7 breast carcinoma cells overexpressing FGF-1 form vascularized, metastatic tumors in ovariectomized and tamoxifen-treated nude mice. *Cancer Res.* in press
42. Johns , D.G., and Bertino, J. R.: Folate antagonist. In: Holland, J. F. and Frei, E., (eds). *Cancer Medicine*. Philadelphia: Lea and Febiger 1973; pp 739-754
43. Salmon, S. and Sartorelli, A. C. 1992. Cancer chemotherapy in Basic and Clinical Pharmacology Katzung, 5th edition, B. G. ed. Prentice Hall, Conneticut, pp. 766-800
44. Kulkarni, P. N., Blair, A. H., and Ghose, T.: 1981. Covalent binding of methotrexate to immunoglobulins and the effect of antibody-linked drug on tumor growth in vivo. *Cancer Res.* 41: 2700-2706.
45. Kanelloes, J., Pietersz, G. A., and McKenzie, I. F.C.: 1985. Studies of methotrexate-monoclonal antibody conjugates for immunotherapy. *JNCI* 75: 319-332.
46. Fritzpatrick, J. J. and Garnett, M. C. 1995. Studies on the mechanism of action of an MTX-HSA-MoAB conjugate. *Anti-canc Drug Design* 10:11-24
47. Tengblad, A. 1979. Affinity chromatography on immobilized hyaluronate and its application to the isolation of hyaluronate binding proteins from cartilage. *Biochim. Phiohys. Acta*, 578:281-289

ACRONYMS AND SYMBOL DEFINITIONS

[³ H]HA	Tritium labeled hyaluronan.
b-Hermes-1	Biotinylated form of the hermes-1 monoclonal antibody - used for the localization of human CD44.
b-KM-201 mAb	Biotinylated form of the KM-201 mAB
b-PG	Biotinylated proteoglycan - used as specific staining probe for hyaluronan.
CD44	Cluster of determination (differentiation) - same as the hyaluronan receptor or binding site.
CMF-PBS	Calcium and magnesium free phosphate buffered saline.
DMEM	Dulbecco's modified Eagle's medium
HA	Hyaluronan.
HAase	Hyaluronidase (either testicular or <i>Streptomyces</i>)
Hermes-1 mAb	Monoclonal antibody against human CD44 - blocks the interaction with hyaluronan.
K-3 mAb	Monoclonal antibody against hamster CD44 - blocks the interaction with hyaluronan.
KM-201 mAb	KM-201 monoclonal antibody directed against mouse CD44 - blocks the interaction with hyaluronan.
mAb	Monoclonal antibody.
MTX	Methotrexate, a cell-cycle dependent chemotherapeutic agent.
MTX-PG	A derivative of MTX coupled to the PG complex.
PG	A complex of a trypsin fragment of cartilage proteoglycan and link protein that binds to HA with high affinity and specificity.
RFS	Rat fibrosarcoma cell line that express large amounts of HA on its surface.
SDS-PAGE	Sodium dodecyl sulfate polyacrylamide gel electrophoresis.
SV-3T3	Simian virus 40 transformed mouse 3T3 cells (Swiss mouse).